Xinwen Chen

Jan 21, 2025 | nature.com | Yongzhi Lu |Qi Yang |Ting Ran |Wei Zhang |Deyin Guo |Xinwen Chen | +1 more

Correction to: Nature Communications https://doi.org/10.1038/s41467-024-54462-0, published online 23 November 2024In this article there is an error in Figure 1 where the residue labelling incorrectly read E164 and should be D164. The original article has been corrected.

Nov 22, 2024 | nature.com | Yongzhi Lu |Qi Yang |Ting Ran |Wei Zhang |Deyin Guo |Xinwen Chen | +1 more

AbstractThe RNA-dependent RNA polymerase (RdRp), 3C-like protease (3CLpro), and papain-like protease (PLpro) are pivotal components in the viral life cycle of SARS-CoV-2, presenting as promising therapeutic targets. Currently, all FDA-approved antiviral drugs against SARS-CoV-2 are RdRp or 3CLpro inhibitors. However, the mutations causing drug resistance have been observed in RdRp and 3CLpro from SARS-CoV-2, which makes it necessary to develop antivirals with novel mechanisms.